Like the findings from the entire cohort, CD34+ cell dose (both as a continuous variable and dichotomized as low vs. high group) was not associated with grade 3–4 acute GVHD or moderate to severe chronic GVHD in either the MRDpos or MRDneg subset of patients. Here, CD34 is linked to chronic graft versus host disease.